The Politics of Vaccination
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Immunizations for Preteens
INVITED COMMENTARY Immunizations for Preteens Emmanuel B. Walter, Richard J. Chung As a part of health supervision visits, all preteens should figure 1. receive the combined tetanus, diphtheria, and pertussis vac- Immunizations Universally Recommended for North cine, the meningococcal conjugate vaccine, the human pap- Carolina Preteens 11-12 Years of Age illomavirus vaccine series, and an annual influenza vaccine. Because levels of vaccine coverage among preteens are gen- Meningococcal conjugate vaccine First dose (to be followed by a second dose at age 16 years). erally suboptimal, strategies for improving coverage should Tetanus, diphtheria, pertussis vaccine be devised and implemented. Human papillomavirus vaccine 3 doses mmunizations are a major component of health supervi- Females – either HPV4 or HPV2 Ision visits for children and adolescents. Because immuni- Males – HPV4 zation recommendations change frequently, Bright Futures, Influenza vaccine an initiative of the American Academy of Pediatrics (AAP) Yearly that promotes the health of children and adolescents, has 2010 [3, 4]. In 2010, only 14 cases were reported in North issued guidelines that refer providers to the Web sites of the Carolina, and 11 of those cases were caused by serogroups Centers for Disease Control and Prevention (CDC) [1] and included in the current vaccine [4]. Although meningococ- the AAP [2] for the most up-to-date immunization sched- cal disease is uncommon, vaccination is critical, because the ules. For no other age group have routine immunization rec- consequences of infection can be devastating. ommendations evolved more rapidly in the past 8 years than In 2005 the US Food and Drug Administration (FDA) for preteens. -
The Golden Bough (Third Edition, Vol. 3 of 12) by James George Frazer
The Project Gutenberg EBook of The Golden Bough (Third Edition, Vol. 3 of 12) by James George Frazer This eBook is for the use of anyone anywhere at no cost and with almost no restrictions whatsoever. You may copy it, give it away or re-use it under the terms of the Project Gutenberg License included with this eBook or online at http://www.gutenberg.org/license Title: The Golden Bough (Third Edition, Vol. 3 of 12) Author: James George Frazer Release Date: January 12, 2013 [Ebook 41832] Language: English ***START OF THE PROJECT GUTENBERG EBOOK THE GOLDEN BOUGH (THIRD EDITION, VOL. 3 OF 12)*** The Golden Bough A Study in Magic and Religion By James George Frazer, D.C.L., LL.D., Litt.D. Fellow of Trinity College, Cambridge Professor of Social Anthropology in the University of Liverpool Third Edition. Vol. III. Part II Taboo and the Perils of the Soul New York and London MacMillan and Co. 1911 Contents Preface. .2 Chapter I. The Burden Of Royalty. .6 § 1. Royal and Priestly Taboos. .6 § 2. Divorce of the Spiritual from the Temporal Power. 24 Chapter II. The Perils Of The Soul. 35 § 1. The Soul as a Mannikin. 35 § 2. Absence and Recall of the Soul. 39 § 3. The Soul as a Shadow and a Reflection. 93 Chapter III. Tabooed Acts. 122 § 1. Taboos on Intercourse with Strangers. 122 § 2. Taboos on Eating and Drinking. 138 § 3. Taboos on shewing the Face. 143 § 4. Taboos on quitting the House. 146 § 5. Taboos on leaving Food over. 150 Chapter IV. -
List of Participants As of 30 April 2013
World Economic Forum on Africa List of Participants As of 30 April 2013 Addis Ababa, Ethiopia, 9-11 May 2012 Messumbe Stanly Paralegal The ABENG Law Firm Cameroon Abane Yilkal Abate Secretary-General ICT Association of Ethiopia Ethiopia Zein Abdalla Chief Executive Officer PepsiCo Europe Switzerland Amin Abdulkader Minister of Culture and Tourism of Ethiopia Rakeb Abebe Chief Executive Officer and Founder GAWT International Business Ethiopia Plc Olufemi Adeyemo Group Chief Financial Officer Oando Plc Nigeria Tedros Adhanom Minister of Health of Ethiopia Ghebreyesus Tedros Adhanom Minister of Health of Ethiopia Ghebreyesus Olusegun Aganga Minister of Industry, Trade and Investment of Nigeria Alfredo Agapiti President Tecnoservice Srl Italy Pranay Agarwal Principal Adviser, Corporate Finance MSP Steel & Power Ltd India and Strategy Vishal Agarwal Head, sub-Saharan Africa Deals and PwC Kenya Project Finance Pascal K. Agboyibor Managing Partner Orrick Herrington & Sutcliffe France Manish Agrawal Director MSP Steel & Power Ltd India Deborah Ahenkorah Co-Founder and Executive Director The Golden Baobab Prize Ghana Halima Ahmed Political Activist and Candidate for The Youth Rehabilitation Somalia Member of Parliament Center Sofian Ahmed Minister of Finance and Economic Development of Ethiopia Dotun Ajayi Special Representative to the United African Business Roundtable Nigeria Nations and Regional Manager, West Africa Abi Ajayi Vice-President, Sub-Saharan Africa Bank of America Merrill Lynch United Kingdom Coverage and Origination Clare Akamanzi Chief Operating Officer Rwanda Development Board Rwanda (RDB) Satohiro Akimoto General Manager, Global Intelligence, Mitsubishi Corporation Japan Global Strategy and Business Development Adetokunbo Ayodele Head, Investor Relations Oando Plc Nigeria Akindele Kemi Lala Akindoju Facilitator Lufodo Academy of Nigeria Performing Arts (LAPA) World Economic Forum on Africa 1/23 Olanrewaju Akinola Editor This is Africa, Financial Times United Kingdom Vikram K. -
Combined Live Measles-Mumps Virus Vaccine ROBERT E
Arch Dis Child: first published as 10.1136/adc.48.7.532 on 1 July 1973. Downloaded from Archives of Disease in Childhood, 1973, 48, 532. Combined live measles-mumps virus vaccine ROBERT E. WEIBEL, VICTOR M. VILLAREJOS, GUILLERMO HERNANDEZ C., JOSEPH STOKES, JR.,* EUGENE B. BUYNAK, and MAURICE R. HILLEMAN From the Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; Louisiana State University International Center for Medical Research and Training, San Jose, Costa Rica; and the Division of Virus and Cell Biology Research, Merck Institutefor Therapeutic Research, West Point, Pennsylvania, U.S.A. Weibel, R. E., Villarejos, V. M., Hernandez C., G., Stokes, J., Jr., Buynak, E. B., and Hilleman, M. R. (1973). Archives of Disease in Childhood, 48, 532. Combined live measles-mumps virus vaccine. Four lots of combined bivalent live Moraten measles-Jeryl Lynn mumps virus vaccine were administered to a total of 334 children 10 months to 6 years of age, who were initially without antibody against either virus. Overall, 99 % of the children responded serologically to the measles virus and 96 % to mumps. The geometric mean titres were of the same general height as those obtained when the individual vaccines were given alone, and there was no indication of immunological suppression. There was no increase in clinical reaction beyond the mild fever and other reactions that follow the administration of Moraten measles vaccine given alone. The combined measles-mumps vaccine provides a simple means for immunization against both these viruses with no apparent alteration in the immunological or clinical responses. copyright. The need to simplify administration, reduce costs, children) (Mumpsvax) for control purpose. -
Full Text (PDF)
ASSESSMENT: NEUROLOGIC RISK OF IMMUNIZATION Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Gerald M. Fenichel, MD Immunization programs are among the most cost-effective public health measures. They are the first line of defense against infectious disease, and when abandoned, epidemics often follow. Vaccines are biological products and some differences exist from lot to lot. Although no vaccine is 100% effective or safe, modern vaccines have an excellent safety record. Smallpox was eradicated by a global immunization program, and the eradication of poliomyelitis is within reach for the year 2000. Physicians are quick to blame vaccines for adverse neurologic events that follow immunizations. This bias probably originated with the first vaccines for rabies. They were grown in the CNS of mature animals, contained myelin basic protein, and often caused encephalomyelitis. In fact, no vaccine currently licensed for use in the United States is known to cause or exacerbate a demyelinating disorder of the CNS. The United States maintains the most extensive obligatory childhood immunization schedule of any country, but has one of the worst records of infant immunization (table 1). The main reasons for the low immunization rate are deficiencies in health care delivery and access in the public sector. Full immunization is only realized at age 5, when it becomes prerequisite for school entry. Immunization practices are recommended to the Surgeon General by the Advisory Committee on Immunization Practices (ACIP) of the Centers of Disease Control and Prevention. New recommendations of the ACIP are published in Morbidity and Mortality Weekly Reports and are the standard of care for immunization practice. -
Polio Vaccine Safety Paul Meier's Role in the Discovery And
www.barkerstats.com Polio Vaccine the cutter incident October 1, 2020 Downloaded from www.barkerstats.com/PDFs/Meier/Meier-Cutter-Incident-History.pdf Polio Vaccine Safety Paul Meier’s Role in the Discovery and Evaluation of The Cutter Incident Professor Chris Barker, Ph.D. Adjunct Associate Professor of Biostatistics, UIC SPH. www.barkerstats.com Page 1 of 11 www.barkerstats.com Polio Vaccine the cutter incident October 1, 2020 Contents Background .................................................................................................................................................................................................................... 3 Brief Polio Vaccine Overview ......................................................................................................................................................................................... 3 Polio Vaccine Manufacturing Data Suppression ............................................................................................................................................................ 4 Biological Disaster? How Serious was the vaccine manufacturing problem? ............................................................................................................... 5 Near Elimination of Vaccine development by lawsuits ................................................................................................................................................. 6 Meier’s evaluation of the safety recommendations following The Cutter Incident .................................................................................................... -
Vaccinator Training Module
SUPPLEMENTARY IMMUNIZATION ACTIVITIES Vaccinator Training Module Revised March 2005 Operations and Interpersonal Communication Prepared by National Polio Surveillance Project-India (A Government of India & World health Organization collaboration) 1 Ensure that you have covered all of the following issues in your training session 1. Introduced all the vaccinators and supervisors. 2. Reviewed the current status of polio eradication and complimented vaccinators on their achievements. 3. The pre-booth preparations including identification and interaction with local influencers. 4. Booth day preparations 5. VVM, open vial policy and Cold Chain management. 6. House to house activities including a. How to enter the home and initiate a dialogue with the family members b. Ensuring cordiality c. Key questions to be asked in each house d. Responding to queries from parents (with help of frequently asked questions and role plays) e. Procedure for immunizing the child f. Finger marking of the child g. House and tally sheet marking 2 BEFORE STARTING THE TRAINING SESSION Before conducting the training, make sure you have: Scheduled the training session in consultation with the Block Medical Officer. The date and time for the training and the venue has to be clearly conveyed to the vaccinators and supervisors. You will need the following materials: • Micro plan for the A team activities in the block/urban area to be covered with the names of the vaccinators and local influencers. • Vaccine carrier and ice packs to demonstrate proper use • OPV vials to demonstrate the VVM and proper administration of the vaccine • Marker pen to demonstrate finger marking • Chalk or geru to demonstrate house marking • Tally sheets to demonstrate how they should be filled in SESSION I KNOWING EACH OTHER REGISTRATION Before starting the session ensure that all participants are registered. -
And Gardasil
Advisory Commission on Childhood Vaccines (ACCV) Food and Drug Administration Update March 4, 2021 CDR Valerie Marshall, MPH, PMP, GWCPM Immediate Office of the Director Office of Vaccines Research and Review (OVRR) Center for Biologics Evaluation and Research (CBER) Food and Drug Administration (FDA) 1 Emergency Use Authorization for Vaccines . An Emergency Use Authorization (EUA) is a mechanism to facilitate the availability and use of medical countermeasures, including vaccines, during public health emergencies, such as the current COVID-19 pandemic. Under an EUA, the FDA may allow the use of unapproved medical products to prevent serious or life-threatening diseases or conditions when certain statutory criteria have been met, including that there are no adequate, approved, and available alternatives. Taking into consideration input from the FDA, manufacturers decide whether and when to submit an EUA request to FDA. Once submitted, FDA will evaluate an EUA request and determine whether the relevant statutory criteria are met, and review the scientific evidence about the vaccine that is available to FDA. 2 Requirements for the EUA . FDA evaluated nonclinical, clinical, and manufacturing data submitted by a vaccine manufacturer. For an EUA to be issued for a vaccine: . Adequate manufacturing information ensures quality and consistency . Vaccine benefits outweigh its risk based on data from at least one well-designed Phase 3 clinical study that in a compelling manner demonstrates: . Safety . Efficacy 3 Continued monitoring of COVID-19 Vaccines Authorized by FDA . USG Systems: . Vaccine Adverse Event Reporting System (VAERS) . Vaccine Safety Datalink (VSD), . Biologics Effectiveness and Safety (BEST) Initiative . Medicare Claims Data 4 EUA of COVID-19 Vaccines • On December 11, 2020, the FDA issued the first emergency use authorization (EUA) for Pfizer’s COVID-19 Vaccine. -
Technical Note the Use of Oral Cholera Vaccines for International Workers and Travelers to and from Cholera-Affected Countries November 2016
Global Task Force on Cholera Control (GTFCC) Oral Cholera Vaccine Working Group Technical Note The Use of Oral Cholera Vaccines for International Workers and Travelers to and from Cholera-Affected Countries November 2016 Background Three Oral Cholera Vaccines (OCVs) are currently pre-qualified by WHO: Dukoral® – a vaccine used mainly by travelers that includes killed whole cells and a component of the cholera toxin – and Shanchol™ and Euvichol®, which contain only killed whole cells. All three vaccines have a two-dose regimen with an interval between doses of two weeks or more (three doses for Dukoral® in children aged 2–5 years). All also have a good safety profile. Shanchol™ and Euvichol® are have the same formulation and comparable safety and immunogenicity profiles and are reformulated versions of Dukoral®.1,2 Unlike Dukoral®, Shanchol™ and Euvichol® do not require a buffer to administer. Shanchol™ has demonstrated longer term protection – a rather stable 65 – 67% from Year 2 to Year 5,3,4,5 as compared to Dukoral®.6 Concerning short-term protection – of most relevance to travelers – Dukoral® has been shown to provide 79-86% for three to six months in a series of studies,4,7,8,9 while the single published study of the short-term effectiveness of Shanchol™ found a similar rate (87%) over six months.10 Dukoral® has been shown to also confer significant short-term protection against enterotoxigenic E. coli (ETEC).11 Purpose of the Technical Note Concern has been raised in the past several years about the risk of international workers and other travelers getting cholera while in an endemic country or a country affected by an outbreak. -
Vaccine Information for PARENTS and CAREGIVERS
NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES Division of the National Health Laboratory Service VACCINE INFOR MATION FOR PARENTS & CAREGIVERS First Edition November 2016 Editors-in-Chief Nkengafac Villyen Motaze (MD, MSc, PhD fellow), Melinda Suchard (MBBCh, FCPath (SA), MMed) Edited by: Cheryl Cohen, (MBBCh, FCPath (SA) Micro, DTM&H, MSc (Epi), Phd) Lee Baker, (Dip Pharm) Lucille Blumberg, (MBBCh, MMed (Micro) ID (SA) FFTM (RCPS, Glasgow) DTM&H DOH DCH) Published by: Ideas Wise and Wonderful (IWW) for National Institute for Communicable Diseases (NICD) First Edition: Copyright © 2016 Contributions by: Clement Adu-Gyamfi (BSc Hons, MSc), Jayendrie Thaver (BSc), Kerrigan McCarthy, (MBBCh, FCPath (SA), DTM&H, MPhil (Theol) Kirsten Redman (BSc Hons), Nishi Prabdial-Sing (PhD), Nonhlanhla Mbenenge (MBBCh, MMED) Philippa Hime (midwife), Vania Duxbury (BSc Hons), Wayne Howard (BSc Hons) Acknowledgments: Amayeza, Vaccine Information Centre (http://www.amayeza-info.co.za/) Centre for Communicable Diseases Fact Sheets (http://www.cdc.gov/vaccines/hcp/vis/) World Health Organization Fact Sheets (http://www.who.int/mediacentre/factsheets/en/) National Department of Health, South Africa (http://www.health.gov.za/) Disclaimer This book is intended as an educational tool only. Information may be subject to change as schedules or formulations are updated. Summarized and simplified information is presented in this booklet. For full prescribing information and contraindications for vaccinations, please consult individual package inserts. There has been -
Tuesday, September 24, 2019 Council Chambers Room 1098 405 E Loop Street, Building 100 Buda, TX 78610
NOTICE OF MEETING OF THE PLANNING AND ZONING COMMISSION OF BUDA, TX 7:00 PM - Tuesday, September 24, 2019 Council Chambers Room 1098 405 E Loop Street, Building 100 Buda, TX 78610 This notice is posted pursuant to the Texas Open Meetings Act. Notice is hereby given that a Regular Planning & Zoning Meeting of the City of Buda, TX, will be held at which time the following subjects will be discussed and may be acted upon. A. CALL TO ORDER B. INVOCATION C. PLEDGE OF ALLEGIANCE TO THE FLAGS OF THE UNITED STATES AND TEXAS PLEDGE OF ALLEGIANCE TO THE TEXAS FLAG: Honor the Texas flag; I pledge allegiance to thee, Texas, one state under God, one and indivisible. ROLL CALL Chair Colin Strother Vice-Chair Meghan McCarthy Commissioner Henry Altmiller Commissioner Sam Ardekani Commissioner E. Scott Ross Commissioner Clark Beach Commissioner Jake Snyder D. PUBLIC COMMENTS At this time, comments will be take from the audience on non-agenda related topics, for a length of time not to exceed three minutes per person. To address the Planning and Zoning Commission (P&Z), please submit a Citizen's Comment Form to the City Liaison prior to the start of the meeting. No action may be taken by the P&Z during Public Comments. E. CONSENT AGENDA E.1. Approval of the regular Planning and Zoning Commission meeting minutes dated August 27, 2019. F1 Minutes from 08-27-2019.pdf F. PUBLIC HEARINGS 1 Planning and Zoning Commission Agenda Page 1 September 24, 2019 F.1. Hold a Public Hearing regarding the proposed Specific Use Permit for a Grocery, Market in the F5H zoning district for the property known as Buda Mill and Grain Development District, Lot 1, Hays County, TX, being +/- 8.06 acres and addressed as 306 S. -
Immunization-Form.Pdf
James Madison University Immunization Form COMMONWEALTH OF VIRGINIA LAW REQUIRES THAT THE CERTIFICATE OF IMMUNIZATION AND TB SCREENING BE COMPLETED AND SUBMITTED TO THE UNIVERSITY HEALTH CENTER. Instructions for new students: 1) Download (if .pdf does not display correctly, open the file in Adobe Reader) and print the Immunization Form and have it completed and signed by a health care professional. An official immunization record from your doctor or another school will be accepted. 2) Log into your MyJMUChart account to upload the completed and signed immunization form (or official record), as well as a copy of your health insurance card (front and back.) All uploaded forms must be in .pdf format. Immunizations must be up to date. 3) Complete the required TB Assessment and Health History for NEW students located under the “forms” tab in MyJMUChart. Due dates for undergraduate students: July 8, 2021 for Fall 2021 semester start and December 10, 2021 for Spring 2022 start. Due date for graduate students: No later than the third Friday of the first semester attending JMU. An enrollment hold and a $50 fine will be placed on your account if your immunization form and TB Screening are not deemed complete by the Health Center staff. CERTIFICATE OF IMMUNIZATION* This MUST be signed by a health care provider Name (print): _______________________________________________ Date of Birth: ______/_______/_______________ Date completed: _______/_______/_______ STUDENT ID NUMBER: __________________________ REQUIRED IMMUNIZATIONS COVID-19 (indicate which